[{"id":"cd1de8a7-094e-49cc-8165-4980d260787c","acronym":"SKYBRIDGE","url":"https://clinicaltrials.gov/study/NCT05652686","created_at":"2022-12-15T14:58:20.111Z","updated_at":"2025-02-25T16:27:12.251Z","phase":"Phase 1/2","brief_title":"A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","source_id_and_acronym":"NCT05652686 - SKYBRIDGE","lead_sponsor":"Phanes Therapeutics","biomarkers":" EGFR • DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["EGFR • DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • paclitaxel • etoposide IV • peluntamig (PT217)"],"overall_status":"Recruiting","enrollment":" Enrollment 203","initiation":"Initiation: 09/05/2023","start_date":" 09/05/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-01-31"}]